肺氣腫治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球肺氣腫治療市場規模達47億美元，預計2034年將以4.7%的複合年成長率成長，達到75億美元。肺氣腫是一種慢性呼吸系統疾病，會對肺泡造成永久性損傷，導致呼吸困難，並降低人體維持健康氧含量的能力。儘管該疾病無法逆轉，但治療策略著重於控制症狀、最大程度減少病情惡化以及增強肺功能，從而改善生活品質。隨著醫療保健提供者重視早期介入、慢性病管理和改善患者預後，該市場正在穩步成長。

肺部健康意識的提升、非侵入性診斷技術的進步以及呼吸治療的普及也推動了這一成長。諸如針對慢性阻塞性肺病 (COPD) 患者的遠距醫療諮詢、數位吸入器以及針對特定患者的康復計劃等創新正在改變肺氣腫的治療方式。各國政府和私人醫療機構正在進行廣泛的篩檢項目，鼓勵病患儘早醫。隨著醫療技術的不斷發展，越來越多的人能夠及時獲得診斷，並獲得針對自身需求的個人化治療。隨著全球人口老化、城市污染水平不斷上升以及長期吸煙等生活方式因素的影響，全球對先進肺氣腫治療方案的需求正在不斷成長。

隨著全球醫療體系將慢性呼吸系統疾病的主動管理置於優先地位，肺氣腫治療市場正在蓬勃發展。老化人口尤其容易出現肺部退化，而肺氣腫仍然是慢性阻塞性肺病 (COPD) 最常見的診斷形式之一。工業污染物、職業粉塵和城市空氣毒素的暴露顯著提高了已開發經濟體和新興經濟體的發生率。儘管一些國家的吸煙率正在下降，但吸煙仍然是新增肺氣腫病例的重要原因。公共衛生運動的加強和肺部篩檢的普及有助於在早期發現疾病，從而能夠及時干預並制定長期護理計劃。

藥物療法繼續主導肺氣腫治療領域，2024 年將佔 62.6% 的市場。隨著全球慢性阻塞性肺病 (CPD) 病例的增加，針對氣道發炎、支氣管收縮和感染預防的藥物干預措施仍然至關重要。持續的藥物創新正在改善肺部功能，並改善患者的日常生活。呼吸系統藥物研發投資的不斷增加必將加速未來市場的擴張。

依疾病類型分類，2024年，肺泡中心型肺氣腫市場規模達27億美元。此亞型主要與慢性吸菸有關，在慢阻肺（COPD）患者中較為常見。民眾對吸菸相關疾病的認知不斷提高，以及衛生法規的加強，正在推動對以肺部復健和症狀管理為重點的肺泡中心型肺氣腫特異性治療方案的需求。

預計到 2034 年，美國肺氣腫治療市場規模將達到 32 億美元。人口老化、慢性肺病發病率上升、全面的報銷框架以及更好的保險滲透率，正在推動全國範圍內大力採用藥物治療和非侵入性呼吸護理服務。

全球肺氣腫治療市場的領導者包括雅培實驗室、勃林格殷格翰、凱西製藥、奧林巴斯、諾華、波士頓科學、美敦力、阿斯特捷利康、葛蘭素史克、荷蘭皇家飛利浦、泰利福、瑞思邁、百特國際、Pulmonx Corporation 和 Grifols。各公司正大力投資研發，透過策略合作和授權合作，將先進的複合吸入器、長效支氣管擴張劑、再生肺療法和非侵入性治療設備推向市場。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 慢性阻塞性肺病盛行率不斷上升
    • 微創治療的進展
    • 老年人口不斷增加
  • 產業陷阱與挑戰
    • 先進療法和治療費用高昂
    • 發展中地區的認知與診斷有限
• 成長潛力分析
• 監管格局
• 技術格局
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依治療類型，2021 年至 2034 年

• 主要趨勢
• 藥物
  • 支氣管擴張劑
  • 類固醇
  • 其他藥物
• 外科手術干預
  • 肺減容手術（LVRS）
  • 肺大泡切除術
  • 肺移植
• 氧氣治療

第6章：市場估計與預測：按類型，2021 年至 2034 年

• 主要趨勢
• 中心泡
• 帕納希納爾
• 隔旁

第7章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 專科診所
• 門診手術中心
• 居家照護環境

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Abbott Laboratories
• AstraZeneca
• Baxter International
• Boehringer Ingelheim
• Boston Scientific Corporation
• Chiesi Farmaceutici
• GlaxoSmithKline
• Grifols
• Koninklijke Philips
• Medtronic
• Novartis
• Olympus Corporation
• Pulmonx Corporation
• ResMed
• Teleflex

The Global Emphysema Treatment Market was valued at USD 4.7 billion in 2024 and is estimated to grow at a CAGR of 4.7% to reach USD 7.5 billion by 2034. Emphysema, a chronic respiratory condition, causes permanent damage to the alveoli in the lungs, making breathing increasingly difficult and reducing the body's ability to maintain healthy oxygen levels. Even though the disease cannot be reversed, treatment strategies focus on managing symptoms, minimizing exacerbations, and enhancing lung function to improve quality of life. The market is steadily growing as healthcare providers emphasize early intervention, chronic disease management, and improved patient outcomes.

Rising awareness about pulmonary health, advancements in non-invasive diagnostics, and wider access to respiratory therapies are also fueling growth. Innovations like telemedicine consultations for COPD patients, digital inhalers, and patient-specific rehabilitation programs are changing the way emphysema is managed. Governments and private health organizations are running extensive screening programs, encouraging patients to seek medical advice earlier. As medical technology continues to evolve, more people are receiving timely diagnoses and accessing therapies tailored to their specific needs. With an aging global population, escalating urban pollution levels, and lifestyle factors like prolonged smoking habits, the need for sophisticated emphysema treatment options is expanding worldwide.

The emphysema treatment market is gaining momentum as global healthcare systems prioritize proactive management of chronic respiratory diseases. Aging demographics are particularly susceptible to lung degeneration, and emphysema remains one of the most commonly diagnosed forms of COPD. Exposure to industrial pollutants, occupational dust, and urban air toxins is significantly raising disease incidence across developed and emerging economies. Although smoking rates are declining in some countries, it still contributes heavily to new emphysema cases. Increased public health campaigns and widespread availability of pulmonary screenings are helping detect the condition at earlier stages, enabling timely intervention and long-term care planning.

Medication-based therapies continue to dominate the emphysema treatment landscape, accounting for 62.6% of the market share in 2024. As chronic obstructive pulmonary disease cases rise globally, pharmaceutical interventions targeting airway inflammation, bronchoconstriction, and infection prevention remain critical. Continuous drug innovations are improving lung performance and enhancing patients' day-to-day living. Expanding investments in respiratory drug development are set to accelerate future market expansion.

By disease type, the centriacinar emphysema segment generated USD 2.7 billion in 2024. This subtype, primarily linked to chronic smoking, is widespread among COPD patients. Growing public awareness of smoking-related diseases and stronger health regulations are fostering demand for centriacinar-specific therapeutic options focused on lung rehabilitation and symptom management.

The United States emphysema treatment market is forecasted to reach USD 3.2 billion by 2034. An aging population, increased rates of chronic lung diseases, comprehensive reimbursement frameworks, and better insurance penetration are driving strong adoption of both pharmaceutical treatments and non-invasive respiratory care services across the country.

Leading players in the global emphysema treatment market include Abbott Laboratories, Boehringer Ingelheim, Chiesi Farmaceutici, Olympus Corporation, Novartis, Boston Scientific Corporation, Medtronic, AstraZeneca, GlaxoSmithKline, Koninklijke Philips, Teleflex, ResMed, Baxter International, Pulmonx Corporation, and Grifols. Companies are heavily investing in R&D to bring advanced combination inhalers, long-acting bronchodilators, regenerative lung therapies, and non-invasive treatment devices to market through strategic collaborations and licensing partnerships.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic obstructive pulmonary disease
    • 3.2.1.2 Advancements in minimally invasive treatments
    • 3.2.1.3 Growing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of advanced therapies and treatments
    • 3.2.2.2 Limited awareness and diagnosis in developing regions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medications
  • 5.2.1 Bronchodilators
  • 5.2.2 Steroids
  • 5.2.3 Other medications
• 5.3 Surgical interventions
  • 5.3.1 Lung volume reduction surgery (LVRS)
  • 5.3.2 Bullectomy
  • 5.3.3 Lung transplantation
• 5.4 Oxygen therapy

Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Centriacinar
• 6.3 Panacinar
• 6.4 Paraseptal

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Ambulatory surgical centers
• 7.5 Home care settings

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AstraZeneca
• 9.3 Baxter International
• 9.4 Boehringer Ingelheim
• 9.5 Boston Scientific Corporation
• 9.6 Chiesi Farmaceutici
• 9.7 GlaxoSmithKline
• 9.8 Grifols
• 9.9 Koninklijke Philips
• 9.10 Medtronic
• 9.11 Novartis
• 9.12 Olympus Corporation
• 9.13 Pulmonx Corporation
• 9.14 ResMed
• 9.15 Teleflex